Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Recruiting now

Conditions studied: Monoclonal Gammopathy of Undetermined Significance, Myeloma Multiple

In brief

No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.

Key facts

Study ID

NCT06559033

Run by

University Hospital, Rouen

People needed

300

Starts

2025-10-07

Expected to finish

2027-04-01

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
• Membership of a social security scheme
• Adult having read and understood the information letter and signed the consent form

You may not qualify if…

• Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship

Where it is running

• University Rouen Hospital — Rouen, France (enrolling)
• Centre Henri Becquerel — Rouen, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.